Phase 3 BGB-43395 CDK4-selective inhibitor plus letrozole vs CDK4/6 inhibitors in 1L HR+/HER2- MBC

This open-label, randomized, multicenter Phase 3 study (BeOne Medicines) tests whether BGB-43395—an oral, CDK4-selective small-molecule inhibitor—combined with letrozole (aromatase inhibitor) improves outcomes versus standard CDK4/6 inhibitors (abemaciclib [Eli Lilly], palbociclib [Pfizer], or ribociclib [Novartis]) combined with letrozole in previously untreated advanced/metastatic HR+/HER2- breast cancer. Participants are treated in the first-line metastatic setting, where current care for most patients is endocrine therapy (often an aromatase inhibitor like letrozole) paired with a CDK4/6 inhibitor, with later-line options including fulvestrant- or SERD-based regimens and targeted therapies when biomarkers apply. The scientific/commercial angle is the head-to-head concept: replacing “CDK4/6” with a more selective “CDK4-only” strategy that could preserve efficacy while changing tolerability and/or resistance dynamics in a very large market segment. The comparator arm reflects real-world practice by allowing investigator choice among the three approved CDK4/6 inhibitors.